The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Type-1 Diabetes Treatment Market Research Report 2024
Synopsis
Type-1 diabetes accounts for 5%–10% of all diabetes cases worldwide. Failure to produce insulin is the cause of this type of diabetes.
The global Type-1 Diabetes Treatment market was valued at US$ 5020 million in 2023 and is anticipated to reach US$ 7034.4 million by 2030, witnessing a CAGR of 4.5% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Type-1 Diabetes Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Type-1 Diabetes Treatment.
Report Scope
The Type-1 Diabetes Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Type-1 Diabetes Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Type-1 Diabetes Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Astellas Pharma
Merck
Eli Lilly
Novo Nordisk
Sanofi
AstraZeneca
Boehringer Ingelheim GmbH
Novartis
Pfizer Inc.
Abbott Laboratories
Mannkind Corporation
Braun Melsungen AG
Macrogenics, Inc.
Segment by Type
Rapid-Acting Insulin
Short-Acting Insulin
Others
Segment by Application
Hospitals & Clinics
Academic & Research Institutes
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Type-1 Diabetes Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Type-1 diabetes accounts for 5%–10% of all diabetes cases worldwide. Failure to produce insulin is the cause of this type of diabetes.
The global Type-1 Diabetes Treatment market was valued at US$ 5020 million in 2023 and is anticipated to reach US$ 7034.4 million by 2030, witnessing a CAGR of 4.5% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Type-1 Diabetes Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Type-1 Diabetes Treatment.
Report Scope
The Type-1 Diabetes Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Type-1 Diabetes Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Type-1 Diabetes Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Astellas Pharma
Merck
Eli Lilly
Novo Nordisk
Sanofi
AstraZeneca
Boehringer Ingelheim GmbH
Novartis
Pfizer Inc.
Abbott Laboratories
Mannkind Corporation
Braun Melsungen AG
Macrogenics, Inc.
Segment by Type
Rapid-Acting Insulin
Short-Acting Insulin
Others
Segment by Application
Hospitals & Clinics
Academic & Research Institutes
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Type-1 Diabetes Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Type-1 Diabetes Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Rapid-Acting Insulin
1.2.3 Short-Acting Insulin
1.2.4 Others
1.3 Market by Application
1.3.1 Global Type-1 Diabetes Treatment Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals & Clinics
1.3.3 Academic & Research Institutes
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Type-1 Diabetes Treatment Market Perspective (2019-2030)
2.2 Type-1 Diabetes Treatment Growth Trends by Region
2.2.1 Global Type-1 Diabetes Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Type-1 Diabetes Treatment Historic Market Size by Region (2019-2024)
2.2.3 Type-1 Diabetes Treatment Forecasted Market Size by Region (2025-2030)
2.3 Type-1 Diabetes Treatment Market Dynamics
2.3.1 Type-1 Diabetes Treatment Industry Trends
2.3.2 Type-1 Diabetes Treatment Market Drivers
2.3.3 Type-1 Diabetes Treatment Market Challenges
2.3.4 Type-1 Diabetes Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Type-1 Diabetes Treatment Players by Revenue
3.1.1 Global Top Type-1 Diabetes Treatment Players by Revenue (2019-2024)
3.1.2 Global Type-1 Diabetes Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Type-1 Diabetes Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Type-1 Diabetes Treatment Revenue
3.4 Global Type-1 Diabetes Treatment Market Concentration Ratio
3.4.1 Global Type-1 Diabetes Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Type-1 Diabetes Treatment Revenue in 2023
3.5 Type-1 Diabetes Treatment Key Players Head office and Area Served
3.6 Key Players Type-1 Diabetes Treatment Product Solution and Service
3.7 Date of Enter into Type-1 Diabetes Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Type-1 Diabetes Treatment Breakdown Data by Type
4.1 Global Type-1 Diabetes Treatment Historic Market Size by Type (2019-2024)
4.2 Global Type-1 Diabetes Treatment Forecasted Market Size by Type (2025-2030)
5 Type-1 Diabetes Treatment Breakdown Data by Application
5.1 Global Type-1 Diabetes Treatment Historic Market Size by Application (2019-2024)
5.2 Global Type-1 Diabetes Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Type-1 Diabetes Treatment Market Size (2019-2030)
6.2 North America Type-1 Diabetes Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Type-1 Diabetes Treatment Market Size by Country (2019-2024)
6.4 North America Type-1 Diabetes Treatment Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Type-1 Diabetes Treatment Market Size (2019-2030)
7.2 Europe Type-1 Diabetes Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Type-1 Diabetes Treatment Market Size by Country (2019-2024)
7.4 Europe Type-1 Diabetes Treatment Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Type-1 Diabetes Treatment Market Size (2019-2030)
8.2 Asia-Pacific Type-1 Diabetes Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Type-1 Diabetes Treatment Market Size by Region (2019-2024)
8.4 Asia-Pacific Type-1 Diabetes Treatment Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Type-1 Diabetes Treatment Market Size (2019-2030)
9.2 Latin America Type-1 Diabetes Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Type-1 Diabetes Treatment Market Size by Country (2019-2024)
9.4 Latin America Type-1 Diabetes Treatment Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Type-1 Diabetes Treatment Market Size (2019-2030)
10.2 Middle East & Africa Type-1 Diabetes Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Type-1 Diabetes Treatment Market Size by Country (2019-2024)
10.4 Middle East & Africa Type-1 Diabetes Treatment Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Astellas Pharma
11.1.1 Astellas Pharma Company Detail
11.1.2 Astellas Pharma Business Overview
11.1.3 Astellas Pharma Type-1 Diabetes Treatment Introduction
11.1.4 Astellas Pharma Revenue in Type-1 Diabetes Treatment Business (2019-2024)
11.1.5 Astellas Pharma Recent Development
11.2 Merck
11.2.1 Merck Company Detail
11.2.2 Merck Business Overview
11.2.3 Merck Type-1 Diabetes Treatment Introduction
11.2.4 Merck Revenue in Type-1 Diabetes Treatment Business (2019-2024)
11.2.5 Merck Recent Development
11.3 Eli Lilly
11.3.1 Eli Lilly Company Detail
11.3.2 Eli Lilly Business Overview
11.3.3 Eli Lilly Type-1 Diabetes Treatment Introduction
11.3.4 Eli Lilly Revenue in Type-1 Diabetes Treatment Business (2019-2024)
11.3.5 Eli Lilly Recent Development
11.4 Novo Nordisk
11.4.1 Novo Nordisk Company Detail
11.4.2 Novo Nordisk Business Overview
11.4.3 Novo Nordisk Type-1 Diabetes Treatment Introduction
11.4.4 Novo Nordisk Revenue in Type-1 Diabetes Treatment Business (2019-2024)
11.4.5 Novo Nordisk Recent Development
11.5 Sanofi
11.5.1 Sanofi Company Detail
11.5.2 Sanofi Business Overview
11.5.3 Sanofi Type-1 Diabetes Treatment Introduction
11.5.4 Sanofi Revenue in Type-1 Diabetes Treatment Business (2019-2024)
11.5.5 Sanofi Recent Development
11.6 AstraZeneca
11.6.1 AstraZeneca Company Detail
11.6.2 AstraZeneca Business Overview
11.6.3 AstraZeneca Type-1 Diabetes Treatment Introduction
11.6.4 AstraZeneca Revenue in Type-1 Diabetes Treatment Business (2019-2024)
11.6.5 AstraZeneca Recent Development
11.7 Boehringer Ingelheim GmbH
11.7.1 Boehringer Ingelheim GmbH Company Detail
11.7.2 Boehringer Ingelheim GmbH Business Overview
11.7.3 Boehringer Ingelheim GmbH Type-1 Diabetes Treatment Introduction
11.7.4 Boehringer Ingelheim GmbH Revenue in Type-1 Diabetes Treatment Business (2019-2024)
11.7.5 Boehringer Ingelheim GmbH Recent Development
11.8 Novartis
11.8.1 Novartis Company Detail
11.8.2 Novartis Business Overview
11.8.3 Novartis Type-1 Diabetes Treatment Introduction
11.8.4 Novartis Revenue in Type-1 Diabetes Treatment Business (2019-2024)
11.8.5 Novartis Recent Development
11.9 Pfizer Inc.
11.9.1 Pfizer Inc. Company Detail
11.9.2 Pfizer Inc. Business Overview
11.9.3 Pfizer Inc. Type-1 Diabetes Treatment Introduction
11.9.4 Pfizer Inc. Revenue in Type-1 Diabetes Treatment Business (2019-2024)
11.9.5 Pfizer Inc. Recent Development
11.10 Abbott Laboratories
11.10.1 Abbott Laboratories Company Detail
11.10.2 Abbott Laboratories Business Overview
11.10.3 Abbott Laboratories Type-1 Diabetes Treatment Introduction
11.10.4 Abbott Laboratories Revenue in Type-1 Diabetes Treatment Business (2019-2024)
11.10.5 Abbott Laboratories Recent Development
11.11 Mannkind Corporation
11.11.1 Mannkind Corporation Company Detail
11.11.2 Mannkind Corporation Business Overview
11.11.3 Mannkind Corporation Type-1 Diabetes Treatment Introduction
11.11.4 Mannkind Corporation Revenue in Type-1 Diabetes Treatment Business (2019-2024)
11.11.5 Mannkind Corporation Recent Development
11.12 Braun Melsungen AG
11.12.1 Braun Melsungen AG Company Detail
11.12.2 Braun Melsungen AG Business Overview
11.12.3 Braun Melsungen AG Type-1 Diabetes Treatment Introduction
11.12.4 Braun Melsungen AG Revenue in Type-1 Diabetes Treatment Business (2019-2024)
11.12.5 Braun Melsungen AG Recent Development
11.13 Macrogenics, Inc.
11.13.1 Macrogenics, Inc. Company Detail
11.13.2 Macrogenics, Inc. Business Overview
11.13.3 Macrogenics, Inc. Type-1 Diabetes Treatment Introduction
11.13.4 Macrogenics, Inc. Revenue in Type-1 Diabetes Treatment Business (2019-2024)
11.13.5 Macrogenics, Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
